Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.
Gueorguieva I, Willis BA, Chua L, Chow K, Ernest CS 2nd, Wang J, Shcherbinin S, Sims JR, Chigutsa E. Gueorguieva I, et al. Among authors: willis ba. Alzheimers Dement (N Y). 2023 Jun 28;9(2):e12404. doi: 10.1002/trc2.12404. eCollection 2023 Apr-Jun. Alzheimers Dement (N Y). 2023. PMID: 37388759 Free PMC article.
Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814).
Sims JR, Selzler KJ, Downing AM, Willis BA, Aluise CD, Zimmer J, Bragg S, Andersen S, Ayan-Oshodi M, Liffick E, Eads J, Wessels AM, Monk S, Schumi J, Mullen J. Sims JR, et al. Among authors: willis ba. J Prev Alzheimers Dis. 2017;4(4):247-254. doi: 10.14283/jpad.2017.38. J Prev Alzheimers Dis. 2017. PMID: 29181490 Review.
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
Wessels AM, Tariot PN, Zimmer JA, Selzler KJ, Bragg SM, Andersen SW, Landry J, Krull JH, Downing AM, Willis BA, Shcherbinin S, Mullen J, Barker P, Schumi J, Shering C, Matthews BR, Stern RA, Vellas B, Cohen S, MacSweeney E, Boada M, Sims JR. Wessels AM, et al. Among authors: willis ba. JAMA Neurol. 2020 Feb 1;77(2):199-209. doi: 10.1001/jamaneurol.2019.3988. JAMA Neurol. 2020. PMID: 31764959 Free PMC article. Clinical Trial.
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, Shcherbinin S, Ardayfio P, Sims JR. Lowe SL, et al. Among authors: willis ba. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12112. doi: 10.1002/trc2.12112. eCollection 2021. Alzheimers Dement (N Y). 2021. PMID: 33614890 Free PMC article.
Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
Lowe SL, Duggan Evans C, Shcherbinin S, Cheng YJ, Willis BA, Gueorguieva I, Lo AC, Fleisher AS, Dage JL, Ardayfio P, Aguiar G, Ishibai M, Takaichi G, Chua L, Mullins G, Sims JR. Lowe SL, et al. Among authors: willis ba. J Prev Alzheimers Dis. 2021;8(4):414-424. doi: 10.14283/jpad.2021.56. J Prev Alzheimers Dis. 2021. PMID: 34585215 Clinical Trial.
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, Gueorguieva I, Hauck PM, Brooks DA, Mintun MA, Sims JR. Shcherbinin S, et al. Among authors: willis ba. JAMA Neurol. 2022 Oct 1;79(10):1015-1024. doi: 10.1001/jamaneurol.2022.2793. JAMA Neurol. 2022. PMID: 36094645 Free PMC article. Clinical Trial.
55 results